Does Lilly need Genzyme more than Sanofi?

Eli Lilly's latest pipeline setback for Alzheimer's is adding extra pressure on CEO John Lechleiter to do something dramatic to quickly improve the pharma company's product mix. And that has BNET's Jim Edwards speculating that Lilly should jump in with a better offer for Genzyme, shoving Sanofi aside. After all, over the next four years Lilly faces the loss of patents on drugs that account for 60 percent of its revenue. And Effient has been a bust. The reasoning may be based on nothing but a few facts about Lilly's conundrum tied to Edwards' fertile imagination, but it makes for a fun read. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.